

## Accepted Manuscript

### Synthesis and Biological Activities Evaluation of Sanjuanolidide and its Analogues

Jiada Zhai, Lin Fu, Yuanyuan Li, Rui Zhao, Rui Wang, Hongkuan Deng, Hongliang Liu, Ling Kong, Zhiwei Chen, Feng Sang


PII: S0960-894X(18)30886-2  
DOI: <https://doi.org/10.1016/j.bmcl.2018.11.020>  
Reference: BMCL 26131

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 12 September 2018  
Revised Date: 7 November 2018  
Accepted Date: 9 November 2018

Please cite this article as: Zhai, J., Fu, L., Li, Y., Zhao, R., Wang, R., Deng, H., Liu, H., Kong, L., Chen, Z., Sang, F., Synthesis and Biological Activities Evaluation of Sanjuanolidide and its Analogues, *Bioorganic & Medicinal Chemistry Letters* (2018), doi: <https://doi.org/10.1016/j.bmcl.2018.11.020>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Synthesis and Biological Activities Evaluation of Sanjuanolide and its Analogues

Jiadao Zhai,<sup>a,b,d</sup> Lin Fu,<sup>a,d</sup> Yuanyuan Li,<sup>a,d</sup> Rui Zhao,<sup>c</sup> Rui Wang,<sup>c</sup> Hongkuan Deng,<sup>a</sup> Hongliang Liu,<sup>a</sup> Ling Kong,<sup>a</sup> Zhiwei Chen,<sup>a</sup> and Feng Sang<sup>a,\*</sup>

<sup>a</sup> School of Life Science, Shandong University of Technology, Zibo 255049, PR China

<sup>b</sup> School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, PR China

<sup>c</sup> College of Pharmacy, Nankai University, Tianjin 300350, PR China

\***Corresponding author:** Feng Sang, Phone: (86)-533-2781329, Fax: (86)-533-2781329, E-mail: fengsang@sdut.edu.cn.

<sup>d</sup>**Author Contributions:** These three authors contributed equally to this work.

**Declarations of interest:** none

**Abbreviations:** Ethyl acetate (EtOAc), Dichloromethane (DCM), Chloromethyl methyl ether (MOMCl), *p*-Toluenesulfonic acid (*p*-TsOH), Tetrahydrofuran (THF), 4-Dimethylaminopyridine (DMAP), Tetraphenylporphyrin (TPP).


**ABSTRACT**

Sanjuanolide, psorachalcone A and its seven new analogues were synthesized via a combinatorial strategy by aldol reaction. In order to investigate the effect between electron density in  $\pi$ -conjugated systems and biological activities, several electron-withdrawing and electron-donating groups were introduced at C-4 and the phenolic hydroxyl groups of sanjuanolide. The two natural products and its seven new analogues were investigated for their inhibitory effects against five cancer cell lines. Moreover, the hydroxyisoprenyl group may be important to maintain the biological activities of sanjuanolide.

**Keywords:** Isoprenylated chalcone; Hydroxyisoprenyl group; Natural product; Analogues; Biological activity

Chalcones are abundant in seeds, fruit skin or peel, bark, and flowers of most edible plants. They have been considered derivatives of a three-carbon  $\alpha,\beta$ -unsaturated carbonyl system (1,3-diphenyl-2-propen-1-one) composed of two phenolic rings. Many of the chalcones exhibit important pharmacological properties, such as anti-inflammatory,<sup>1</sup> anti-bacterial,<sup>2</sup> anti-cancer,<sup>3</sup> anti-oxidant,<sup>4</sup> analgesic,<sup>5</sup> and anti-pyretic effects.<sup>6,7</sup> Sanjuanolide, a new isoprenylated chalcone which contains an unique hydroxyisoprenyl group, was isolated from *G. hypoleuca. Dalea frutescens* by Shaffer *et al* in 2016.<sup>8</sup> Specifically, sanjuanolide showed slightly greater cytotoxic activities against PC-3 and DU 145 prostate cancer cell lines.


To our knowledge, the unique hydroxyisoprenyl group was rarely in natural products of chalcones. According to Literature search by reaxys, chalcones with hydroxyisoprenyl at A ring and three-carbon  $\alpha,\beta$ -unsaturated carbonyl system have exhibited cytotoxic or antifungal activities mostly, typically including sanjuanolide (1), psorachalcone A (2),<sup>9</sup> xanthohumol D (3),<sup>10</sup> xanthoangelol D (4),<sup>11</sup> compound 5,<sup>12</sup> paratocarpin E (7),<sup>13</sup> bartericin A (8),<sup>14</sup> angusticornin A (6) and angusticornin B (9)<sup>15</sup> (Figure 1).



**Figure 1. Natural Chalcones with hydroxyisoprenyl group**

However, there is no work has been done on the synthesis of these natural products. In addition, further study of sanjuanolide and its analogues by introduce electron-withdrawing and electron-donating groups at the two aromatic rings may provide new leads for drug discovery. Herein, the first total synthesis of sanjuanolide, psorachalcone A and its seven new analogues are described, and their inhibitory effects against PC-3, A375, PANC-1, A549 and MDA-MB-231 cell lines were investigated.


In consideration of the cytotoxic activity and typical structure, sanjuanolide was selected as the first synthetic target in our laboratory. According to Jean *et al*, photooxygenation of *ortho*-prenylphenols followed by a reduction at low temperature can yield *ortho*-(2-hydroxy-3-methylbut-3-enyl)phenols based on the Schenck reaction.<sup>16</sup> In this work, we intend to obtain the unique hydroxyisoprenyl groups from *ortho*-prenylphenols at the last two steps by retrosynthetic analysis of sanjuanolide (Scheme 1). Disconnection of isocordoin (10) through C3'-C1'' and C,C-double bond in  $\alpha,\beta$ -unsaturated carbonyl system results in three commercialized raw materials 3,3-dimethylallyl bromide (11), 2,4-dihydroxyacetophenone (12) and benzaldehyde (13).



**Scheme 1. Retrosynthetic Analysis of Sanjuanolide (1)**


As described by Jain *et al*,<sup>17</sup> prenylation of 2,4-dihydroxyacetophenone with 2-methylbut-3-en-2-ol in the presence of Lewis acidic medium, was adopted in our laboratory at the beginning. However, by the limit of low yields and high challenge in the process of purification (Low solubility of the two monoprenylated prenylated derivatives in eluent), we used MOM (methoxymethyl) to pro-

protect the C4'-hydroxy group of **12** selectively in 92% yield (Scheme 2). Then the MOM-protected compound **14** was prenylated with bromide **11** to afford **15** (90% yield), which was further reacted with benzaldehyde in the presence of 4 M NaOH to afford chalcone **16** by Claisen-Schmidt condensation (85% yield).<sup>18</sup>



**Scheme 2. Synthesis of sanjuanolid, psorachalcone A and analogues 1b–e.**

Chalcone **16** was subjected to a montmorillonite K10-promoted sigmatropic rearrangement to afford the *ortho*-prenylated chalcone **17** in 35% yield (along with 25% *para*-prenylated chalcone as a by-product).<sup>19</sup> With the intermediate **17** in hand, photooxidation was taken in the presence of tetraphenylporphyrin (TPP) as a photosensitizer. Moreover, we chose the temperature at 10 °C (compare to –30 °C reported by Jean *et al*)<sup>16</sup> to ensure **17** could be converted completely. Then PPh<sub>3</sub> was added to the reaction mixture, and the resulting solution was allowed to warm to room temperature naturally (55% yield). Finally, deprotection of **18** using *p*-TsOH at 50 °C in MeOH/THF afforded synthetic sanjuanolid (**1**), which was obtained as a yellow powder (88% yield).



**Scheme 3. Synthesis of analogues 1f–h.**

Under the same strategy, psorachalcone A (**2**) and **1b–e** were prepared from the corresponding aldehyde **13a–e** using combinatorial approaches. Similarly, **1f** was synthesized starting from intermediate **17** through 3 steps (Scheme 3). Deprotection of the intermediate **17** using *p*-TsOH lead to isocordoin (**10**), which was further reacted with iodomethane or acetic anhydride separately to afford

prenylated chalcones **21** and **22**. And then, after the photooxidation step, analogues **1g** and **1h** were synthesized from **21** and **22** respectively. Additionally, photooxygenation of **10** followed by a reduction can also afford sanjuanolid in 46% yield.

The analytic data of synthetic sanjuanolid were compared with that of the natural sanjuanolid reported in the literatures,<sup>8</sup> including <sup>1</sup>H and <sup>13</sup>C NMR data (Table S1 in the Supporting Information). In addition, as described by Shaffer *et al.*,<sup>8</sup> the configuration of the C-2'' stereocenter in **1** was converted to a virtual (~1:1) racemic mixture after several weeks of freezer storage. In this work, <sup>1</sup>H and <sup>13</sup>C NMR data also showed no discernible changes in these compounds according to our observations, and the samples were investigated as racemic mixtures by chiral HPLC.

The antiproliferative effects of sanjuanolid, psorachalcone A, isocordoin and the seven new analogues were evaluated in five cancer cells, using MTT assays as described in the *in vitro* screening protocol.<sup>20</sup> The ability of these compounds to inhibit the growth of cancer cells was summarized in Table 1. **1c–g** exhibited obvious activity against PC-3 and A375 cell lines. Especially, **1d** exhibited 3.4-fold and 3.0-fold greater potencies against the PC-3 and A375 cells compared to **1** respectively. On the contrary, isoprenylated chalcone **10** and 4-hydroxyl-substituted sanjuanolid (**2**, psorachalcone A) exhibited lower potencies as compared to **1** in PC-3 and A375 cells. In addition, **1f** exhibited moderate levels of activity against PANC-1 and MDA-MB-231 cell lines.

**Table 1. Effects of sanjuanolid and its analogues on proliferation of cancer cell lines.**

Compounds	IC <sub>50</sub> (μM) <sup>1</sup>				
	PC-3	A375	PANC-1	A549	MDA-MB-231
<b>1</b>	17.5	13.1	> 25 <sup>2</sup>	> 25	> 25
<b>2</b>	> 25	> 25	> 25	> 25	> 25
<b>1b</b>	> 25	> 25	> 25	> 25	> 25
<b>1c</b>	16.7	23.5	> 25	> 25	> 25
<b>1d</b>	5.1	4.3	22.5	> 25	23.4
<b>1e</b>	11.4	9.5	24.5	> 25	> 25
<b>1f</b>	13.5	9.2	13.8	> 25	12.1
<b>1g</b>	16.6	18.1	> 25	> 25	> 25
<b>1h</b>	20.4	17.7	> 25	> 25	> 25
<b>10</b>	> 25	23.2	> 25	> 25	> 25

<sup>1</sup> Cells were exposed to compounds for 48 h. All values are the mean of three independent experiments. <sup>2</sup> If a specific compound is given a value >25, it indicates that a specific IC<sub>50</sub> cannot be calculated from the data points collected, meaning “no effect”.

In summary, total synthesis of sanjuanolid, psorachalcone A and its seven new analogues were achieved from commercially available materials in acceptable yields through 6 or 7 steps (12% overall yield for sanjuanolid in 6 steps). Furthermore, this combinatorial approach can also be used for the preparation of chalcones with hydroxyisoprenyl group mentioned above. The compounds were subsequently evaluated for their anti-cancer activities. This preliminary structure-activity relationship study reveals that introducing an electron-withdrawing halogen atom (Cl or F) at C4 position or replace the C2'-hydroxy group with methoxy group may have a positive effect on their biological activities. The relationship between the hydroxyisoprenyl group and biological activities of chalcones still needs to be further investigated.

## Acknowledgments

This work was supported by the National Natural Science Foundation of China (NO. 81602962) and the Natural Science Foundation of Shandong Province (ZR2016HQ04) to F.S.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at xxx

## References

- Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. *Eur. J. Med. Chem.* 2007, 42, 125–137.

2. Nielsen, S. F.; Larsen, M.; Boesen, T.; Schønning, K.; Kromann, H. Cationic chalcone antibiotics. Design, synthesis, and mechanism of action. *J. Med. Chem.* 2005, 48, 2667–2677.
3. Konieczny, M. T.; Konieczny, W.; Sabisz, M.; Skladanowski, A.; Wakieć, R.; Augustynowicz-Kopeć, E.; Zwolska, Z. Synthesis of isomeric, oxathiolone fused chalcones, and comparison of their activity toward various microorganisms and human cancer cells line. *Chem. Pharm. Bull.* 2007, 55, 817–820.
4. Go, M. L.; Wu, X.; Liu, X. L. Chalcones: An update on cytotoxic and chemoprotective properties. *Curr. Med. Chem.* 2005, 12, 483–499.
5. Viana, G. S. B.; Bandeira, M. A. M.; Matos, F. J. A. Analgesic and antiinflammatory effects of chalcones isolated from *Myracrodruon urundeuva* Allemão. *Phytomedicine* 2003, 10, 189–195.
6. Rahim, M. A.; Nakajima, A.; Misawa, N.; Shindo, K.; Adachi, K.; Shizuri, Y.; Ohizumi, Y.; Yamakuni, T. A novel diol-derivative of chalcone produced by bioconversion, 3-(2,3-dihydroxyphenyl)-1-phenylpropan-1-one, activates PKA/MEK/ERK signaling and antagonizes A $\beta$ -inhibition of the cascade in cultured rat CNS neurons. *Eur. J. Pharmacol.* 2008, 600, 10–17.
7. Jung, J.; Lee, Y.; Min, D.; Jung, M.; Oh, S. Practical synthesis of chalcone derivatives and their biological activities. *Molecules* 2017, 22, 1872.
8. Shaffer, C. V.; Cai, S. Peng, J.; Robles, A. J.; Hartley, R. M.; Powell, D. R.; Du, L.; Cichewicz, R. H.; Mooberry, S. L. Texas native plants yield compounds with cytotoxic activities against prostate cancer cells. *J. Nat. Prod.* 2016, 79, 531–540.
9. ElSohly, H. N.; Joshi, A. S.; Nimrod, A. C.; Walker, L. A.; Clark, A. M. Antifungal chalcones from *Maclura tinctoria*. *Planta Med.* 2001, 67, 87–89.
10. Zhao, F.; Nozawa, H.; Daikonnya, A.; Kondo, K.; Kitanaka, S. Inhibitors of nitric oxide production from hops (*Humulus lupulus* L.). *Biol. Pharm. Bull.* 2003, 26, 61–65.
11. Baba, K.; Nakata, K.; Taniguchi, M.; Kido, T.; Kozawa, M. Chalcones from *Angelica Keiskei*. *Phytochemistry* 1990, 29, 3907–3910.
12. Ren, Z. Y.; Qi, H. Y.; Shi, Y. P. Phytochemical investigation of *Anaphalis lactea*. *Planta Med.* 2008, 74, 859–863.
13. Hano, Y.; Itoh, N.; Hanaoka, A.; Itoh, Y.; Nomura, T. Paratocarpins A–E, five new isoprenoid-substituted chalcones from *Paratocarpus venosa* Zoll. *Heterocycles* 1995, 41, 191–198.
14. Ngameni, B.; Ngadjui, B.; Folefoc, G. N.; Watchueng, J.; Abegaz, B. M. Diprenylated chalcones and other constituents from the twigs of *Dorstenia barteri* var. *subtriangularis*. *Phytochemistry* 2004, 65, 427–432.
15. Ngadjui, B. T.; Watchueng, J.; Keumedjio, F.; Ngameni, B.; Simo, I. K.; Abegaz, B. M. Prenylated chalcones, flavone and other constituents of the twigs of *Dorstenia angusticornis* and *Dorstenia barteri* var. *subtriangularis*. *Phytochemistry* 2005, 66, 687–692.
16. Helesbeux, J. J.; Duval, O.; Guilet, D.; Séraphin, D.; Rondeau, D.; Richomme, P. Regioselectivity in the ene reaction of singlet oxygen with *ortho*-prenylphenol derivatives. *Tetrahedron* 2003, 59, 5091–5104.
17. Jain, A. C.; Seshadri, T. R. A study of nuclear prenylation of  $\beta$ -resacetophenone–II: Synthesis of bavachalcone, 4'-O-methylbavachalcone and bavachin. *Tetrahedron* 1970, 26, 2631–2635.
18. Sugamoto, K.; Matsusita, Y.; Matsui, K.; Kurogi, C.; Matsui, T. Synthesis and antibacterial activity of chalcones bearing prenyl or geranyl groups from *Angelica keiskei*. *Tetrahedron* 2011, 67, 5346–5359.
19. Han, J.; Li, X.; Guan, Y.; Zhao, W.; Wulff, W. D.; Lei, X. Enantioselective biomimetic total syntheses of kuwanons I and J and brosimones A and B. *Angew. Chem. Int. Ed.* 2014, 53, 1–6.
20. Liu, S.; Gao, X.; Zhang, L.; Qin, S.; Wei, M.; Liu, N.; Zhao, R.; Li, B.; Meng, Y.; Lin, G.; Lu, C.; Liu, X.; Xie, M.; Liu, T.; Zhou, H.; Qi, M.; Yang, G.; Yang, C. A novel Anti-Cancer Stem Cells compound optimized from the natural symplestatin 4 scaffold inhibits Wnt/ $\beta$ -catenin signaling pathway. *Eur. J. Med. Chem.* 2018, 156, 21–42.
21. Dong, X.; Fan, X.; Yu, L.; Hu, Y. Synthesis of four natural prenylflavonoids and their estrogen-like activities. *Arch. Pharm. Chem. Life Sci.* 2007, 340, 372–376.
22. Caamal-Fuentes, E. E.; Peraza-Sánchez, S. R.; Torres-Tapia, L. W.; Moo-Puc, R. E.; Isolation and Identification of Cytotoxic Compounds from *Aeschynomene fascicularis*, a Mayan Medicinal Plant. *Molecules* 2015, 20, 13563–13574.
23. Nascimento, M. C. D.; Mors, W. B. Chalcones of the root bark of *Derris sericea*. *Phytochemistry* 1972, 11, 3023–3028.

1. First syntheses of two new chalcones with hydroxyisoprenyl group were achieved
2. Preliminary structure-activity relationship study of sanjuanolide was investigated
3. The "hydroxyisoprenyl" group is shown to correlate with anti-tumor activities



